NRx Pharmaceuticals
高管
查看带有其 10 名主要高管的组织结构图
NRx Pharmaceuticals 搜索最多的简介
高管在NRx Pharmaceuticals变化
- Steve Willard, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024十二月5号).
- Michael Abrams已作为Chief Financial Officer加入公司 (新闻发布的2024十一月19号).
创建提醒
跟踪 NRx Pharmaceuticals 的高管变动
药店
NRx Pharmaceuticals 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十二月5号)..
- Recursion Pharma and Exscientia have merged (公布2024十一月27号)..
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
药店 行业的其他推荐联系人
消息
NRx Pharmaceuticals 的最新新闻稿
- NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"
- NRx Pharmaceuticals Investors - Press Releases
- NRx Pharmaceuticals to present at The Emerging Growth Conference, discussing update on HOPE Therapeutics
- NRx Pharmaceuticals Investors - Press Releases
- NRx Pharmaceuticals Investors - Press Releases
- NRx Pharmaceuticals Investors - Press Releases
- NRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipol
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
- NRx Pharmaceuticals Investors - Press Releases
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
- View more press releases Close
通过电子邮件
